Clinical trial
Implementation Study of Treatment Optimization Recommendations on…
NCT00101959 · EMD Serono, Industry · Withdrawn
Key facts
| NCT number | NCT00101959 |
|---|---|
| Title | Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects |
| Official title | An Implementation Study of Treatment Optimization Recommendations Comparing Subjects Continuing Treatment With IFN-ß-1a 30 Mcg qw IM (Avonex®) or Glatiramer Acetate 20 mg qd SC (Copaxone®) to Those Randomized to IFN-ß-1a 44 Mcg Tiw SC (Rebif®), in a Multicenter Study of Subjects With Relapsing… |
| Lead sponsor | EMD Serono, Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Rebif |
| Enrollment | 0 |
| Start date | Nov 1, 2004 |
| First posted | Jan 19, 2005 |
| Last update posted | Aug 6, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: